SVB Leerink analyst Daina Graybosch downgrades Molecular Partners (NASDAQ:MOLN) from Outperform to Market Perform and lowers the price target from $30 to $8.
Keefe, Bruyette & Woods Downgrades Pennant Park Investment to Market Perform, Lowers Price Target to $5.5
Keefe, Bruyette & Woods analyst Ryan Lynch downgrades Pennant Park Investment (NYSE:PNNT) from Outperform to Market Perform and lowers the price target from $7 to $5.5.
